Botanix Pharmaceuticals

➖ Botanix secures commitments for $70 million ➖   #Botanix has received firm commitments for $70 million capital raising via an institutional placement. Funds will be applied towards the launch of Sofdra™ (sofpironium) gel, 12.45%, as well as working capital and costs of the placement. View ASX release 👉 https://lnkd.in/gV-AYFxy $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

📣 FDA Approves Sofdra™ topical gel   #Botanix is very pleased to announce the US FDA approval of Sofdra™ (sofpironium) topical gel, 12.45%. Sofdra is a prescription medicine used to treat primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years and older. View ASX release 👉 https://lnkd.in/gzHx8Q9k $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

🔸 Final Sofdra™ Labelling Discussions with FDA 🔸   #Botanix submitted the last label materials to the US FDA for Sofdra™ a pending prescription treatment for excessive underarm sweating. Labelling, the final step before anticipated Sofdra approval, involves wording of product information for patients and physicians. View the ASX release 👉 https://lnkd.in/gmMbtu6e   $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

"Compelling Opportunity” | E&P Research Report   In new research on Botanix, leading biotech analyst David Nayagam from E&P highlights the “compelling opportunity” that the Company presents and initiates coverage with a speculative buy and $0.55 price target. View E&P Report 👉 https://bit.ly/BOT-EP-Note   $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

🖊️ Euroz Hartleys Analysis – Commercial Day Webinar   Euroz Hartleys Limited's Seth Lizée reviews the Botanix Commercial Day Webinar and maintains a Speculative Buy recommendation with an upgraded $0.33 Price Target. Lizee expressed increased confidence in the late June FDA approval decision and BOT’s commercial strategy. Read the report 👉 https://lnkd.in/gpFJawjk   $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

📺 Video Available – Commercial Day Webinar   Video is now available of the Company’s Commercial Day Webinar presented on 8 May. The expanded commercial team provides market insights and a comprehensive update on commercial launch plans for Sofdra™, which is expected to be approved in late June 2024. Click to view the video 👉 https://lnkd.in/geBEBXnX   $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

📆 8 May Commercial Day Webinar - Registration Open   Join our executive team for the Company’s Commercial Day Webinar on Wednesday 8 May 10:30am AEST / 8:30am AWST to receive a comprehensive update on its commercial launch plans and market insights, as it nears the expected approval of Sofdra™ in late June 2024.   When: Wednesday 8 May 10:30am AEST | 8:30am AWST Pre-register: https://lnkd.in/gvvKX7Nj $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch

📆 Mark your calendar – Commercial Day Webinar   Join our executive team as we outline the key steps #Botanix Pharmaceuticals is taking to prepare to commercialize Sofdra™ for the prescription treatment of primary axillary hyperhidrosis (excessive underarm sweating).    This webinar is an opportunity for investors to gain valuable understanding of our proprietary product, market strategy, and launch plans following the expected approval in late June 2024.   SAVE THE DATE > Wednesday 8 May, 10.30am AEST | 8.30am AWST   Registration details will follow shortly.   $BOT #ASX #dermatology #pharmaceuticals #pharma #biotech #innovation #hyperhidrosis #launch  

🔸 Botanix Included in the All Ordinaries Index 🔸   #Botanix is honoured to announce the Company’s inclusion in the ASX All Ordinaries Index. Botanix joins the ranks of the index, based on its strong performance over the last 12 months, which has been driven by the commercial potential of Sofdra™. Read today’s ASX release 👉 https://lnkd.in/gKPNc4pK $BOT #ASX #health #biotech #medtech #research #innovation #dermatology #invest

🔹 Botanix appoints Graeme Morissey CFO 🔹   #Botanix appoints Graeme Morissey as CFO of the Company effective 25 March 2024. Mr Morissey joins Botanix as a proven CFO with over 17 years’ experience with international accounting firms including Grant Thornton, KPMG Australia, and EY Australia. Read today’s ASX release 👉 https://lnkd.in/gc2bk67x $BOT #ASX #health #biotech #medtech #research #innovation #dermatology #invest